HBM4003 Combine With Toripalimab in Patients With Advanced NEN and Other Solid Tumors Study
Status:
Not yet recruiting
Trial end date:
2024-06-03
Target enrollment:
Participant gender:
Summary
To select RP2D/MTD of HBM4003 in combination with Toripalimab in dose confirmation part(Part
1) and use the RP2D in dose expansion part (Part 2) to evaluate the safety, tolerability,
PK/PD and preliminary efficacy of in patients with advanced NEN and other solid tumors